TRVI
Trevi Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.02B
P/E Ratio
—
EPS
$-0.32
Beta
1.05
52W High
$16.12
52W Low
$5.41
50-Day MA
$14.01
200-Day MA
$11.65
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the development and commercialization of Haduvio to treat serious neurology-mediated conditions. The company is headquartered in New Haven, Connecticut.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-52.63M |
| Operating Margin | 0.00% |
| Return on Equity | -33.60% |
| Return on Assets | -23.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.34 |
| Price-to-Book | 11.10 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -4.92 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $141.98M |
| Float | $117.83M |
| % Insiders | 0.63% |
| % Institutions | 98.30% |
Historical Volatility
HV 10-Day
46.74%
HV 20-Day
48.84%
HV 30-Day
45.57%
HV 60-Day
48.18%
HV Rank
7.9%
Volatility is currently expanding
Analyst Ratings
Consensus ($23.90 target)
2
Strong Buy9
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026